Co-Diagnostics logo
Co-Diagnostics
CODX | NASDAQ
Chart Builder DCF Calculator
$0.47
-$0.08 (-14.12%)
At close: Oct 27, 2026, 4:00 PM ET

Co-Diagnostics Company Profile

Company profile explained

Company Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Key Executives

Name Position
Dwight H. Egan Chairman, CEO & President
Brian L. Brown Chief Financial Officer & Company Secretary
Christopher Thurston Chief Technology Officer
David Nielsen Chief Operating Officer
Andrew Benson Head of Investor Relations
Dan Bohrer Executive VP of Finance & Accounting and Principal Financial & Accounting Officer
Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances
Richard David Abbott President
Seth Egan Chief Commercialization Officer & Strategy Officer
Wesley C. Lindsey Chief Scientific Officer

Latest SEC Filings

Date Type Title
Sep 25, 2026 8-K Current Report
Sep 21, 2026 PRE 14A Filing
Sep 16, 2026 8-K Current Report
Sep 16, 2026 8-K Current Report
Sep 15, 2026 8-K Current Report
Sep 14, 2026 3 Filing
Sep 04, 2026 8-K Current Report
Sep 04, 2026 DEFA14A Filing
Sep 04, 2026 8-K Current Report
Sep 01, 2026 EFFECT Filing
View All SEC Filings ➞
Co-Diagnostics
Co-Diagnostics logo
Country United States
IPO Date Jul 12, 2017
Industry Biotechnology
Sector Healthcare
Employees 115
CEO Dwight Egan

Contact Details

2401 S. Foothill Dr. Salt Lake City, Utah 84109 United States

Stock Details

Ticker Symbol CODX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001692415
CUSIP Number 189763204
ISIN Number US1897632048
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.